Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367357 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL29372643 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL128713 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL21538667 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL353568 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| Iodide SCHEMBL25263727 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL19549028 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| Iodide SCHEMBL21835042 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| Hydrochloric Acid SCHEMBL607840 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 | |
| Hydrochloric Acid SCHEMBL6251235 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1043 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595235-B2 | Process for producing 4,5-dihydro-1H-pyrazoles and intermediates | NOVO NORDISK A/S (DK) | 2026-04-07 | — | — | US | claimed |
| EP-4565233-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | Zydus Lifesciences Limited (IN) | 2025-06-11 | — | — | EP | claimed |
| EP-4539934-A1 | TREATMENT FOR GLOMERULAR DISEASES | Zydus Lifesciences Limited (IN) | 2025-04-23 | — | — | EP | claimed |
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-118064400-B | S-selective omega-aminotransferase mutant with high catalytic activity, and construction method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-06-25 | — | — | CN | claimed |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | ZYDUS LIFESCIENCES LTD. (IN) | 2024-05-30 | — | — | US | claimed |
| CN-118064400-A | S-selective omega-aminotransferase mutant with high catalytic activity, and construction method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-05-24 | — | — | CN | claimed |
| WO-2024064214-A2 | SYNTHESIS OF CYCLOPROPANE CARBOXYLIC ACIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-28 | — | — | WO | claimed |
| WO-2024028744-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-02-08 | — | — | WO | claimed |
| EP-0763513-B1 | Production of optically active 2-halo-1-(substituted phenyl)-ethanol and substituted styrene oxide | NIHON NOHYAKU CO LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| US-6281391-B1 | REACTING HYDROXYAMIDE COMPOUND WITH LITHIATING AGENT COMPRISING 4-METHYLTHIOPHENYLLITHIUM IN NON-REACTING SOLVENT TO FORM METHYLTHIOPHENYL-HYDROXYKETONE COMPOUND | MERCK & CO., INC. | 2001-08-28 | — | — | US | claimed |
| EP-0567438-B1 | Optically pure cis-oxalato(trans-l-1,2-cyclohexanediamine)Pt(II) and process for resolving optical isomers of a platinum complex compound | TANAKA PRECIOUS METAL IND (JP) | 1999-01-13 | — | — | EP | claimed |
| US-5298642-A | Process of optically resoluting optically active platinum complex compound | TANAKA KIKINZOKU KOGYO K.K. (JP) | 1994-03-29 | — | — | US | claimed |
| EP-0567438-A1 | Optically pure cis-oxalato(trans-l-1,2-cyclohexanediamine)Pt(II) and process for resolving optical isomers of a platinum complex compound | Tanaka Kikinzoku Kogyo K.K. (JP) | 1993-10-27 | — | — | EP | claimed |
| EP-0213785-B1 | METHOD FOR OPTICAL RESOLUTION OF DL-CYSTEINE AND (R,S)-1-(1-NAPHTHYL)ETHYLAMINE | NIPPON RIKAGAKUYAKUHIN CO., LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| US-4736060-A | Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine | NIPPON RIKAGAKUYAKUHIN CO., LTD. (JP) | 1988-04-05 | — | — | US | claimed |
| EP-0213785-A1 | Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl)ethylamine | NIPPON RIKAGAKUYAKUHIN CO., LTD. (JP) | 1987-03-11 | — | — | EP | claimed |
| US-4335057-A | 4-(2',2,2'-Trihalogenoethyl)-cyclobutane-1-sulfonic acid salts with optically active bases | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | claimed |
| US-4254279-A | Ester resolution process | FMC CORPORATION (US) | 1981-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595235-B2 | Process for producing 4,5-dihydro-1H-pyrazoles and intermediates | PRMT1, SRM, CHRM1 | ALDH1A1 1603/4885CYP1A2 222/4885CYP2C9 496/4885 |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | HBG1, HBB, HBG2 | ALDH1A1 240/4885CYP1A2 794/4885CYP2C9 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.